# Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant

> **NCT00107354** · PHASE1 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center**

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** therapeutic allogeneic lymphocytes
- **BIOLOGICAL:** therapeutic autologous lymphocytes
- **DRUG:** cytarabine
- **DRUG:** etoposide
- **DRUG:** mitoxantrone hydrochloride
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00107354
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-12
- **Primary completion:** 2009-08
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2010-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00107354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00107354, "Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00107354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*